Ethereum Institutional has named Laurens Schepens, a former UBS executive with extensive experience in bank tokenization, as its Asia-Pacific head based in Singapore. Schepens helped develop UBS Tokenize, supporting Ethereum-based financial products like structured products, funds, bonds, and equities. This appointment aims to strengthen Ethereum Institutional's collaboration with financial firms in the region. The nonprofit plans to hold its next institutional forum in Singapore on Nov. 20, focusing on banking infrastructure and tokenized assets.
Ethereum Institutional's new Asia-Pacific head appointment provides context for readers following cryptocurrency markets. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 02, 2026 16:21 WIB: out of 50 priced major cryptocurrencies, 7 rose and 42 fell. Notable movers include BAL (Balancer) at Rp16.297 with a +11.14% change and EOS (EOS.IO) at Rp12.649 with a +8.13% change, while BAT (Basic Attention Token) fell by -5.75%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
